Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers

• Main Authors: Yi Li (Author), Wei Guo (Author), Xiuqin Li (Author), Jianguo Zhang (Author), Moyi Sun (Author), Zhangui Tang (Author), Wei Ran (Author), Kai Yang (Author), Guilin Huang (Author), Longjiang Li (Author)
• Format: Book
• Published: Nature Publishing Group, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug...